Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
3069 results about "Blood cell" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A blood cell, also called a hematopoietic cell, hemocyte, or hematocyte, is a cell produced through hematopoiesis and found mainly in the blood. Together, these three kinds of blood cells add up to a total 45% of the blood tissue by volume, with the remaining 55% of the volume composed of plasma, the liquid component of blood.
Method and apparatus for non-invasive blood constituent monitoring
InactiveUS6181958B1Repeatable and reliableEasy to implementSensorsBlood characterising devicesNon invasiveHemoglobin G Szuhu
A system for determining a biologic constituent including hematocrit transcutaneously, noninvasively and continuously. A finger clip assembly includes including at least a pair of emitters and a photodiode in appropriate alignment to enable operation in either a transmissive mode or a reflectance mode. At least one predetermined wavelength of light is passed onto or through body tissues such as a finger, earlobe, or scalp, etc. and attenuation of light at that wavelength is detected. Likewise, the change in blood flow is determined by various techniques including optical, pressure, piezo and strain gage methods. Mathematical manipulation of the detected values compensates for the effects of body tissue and fluid and determines the hematocrit value. If an additional wavelength of light is used which attenuates light substantially differently by oxyhemoglobin and reduced hemoglobin, then the blood oxygen saturation value, independent of hematocrit may be determined. Further, if an additional wavelength of light is used which greatly attenuates light due to bilirubin (440 nm) or glucose (1060 nm), then the bilirubin or glucose value may also be determined. Also how to determine the hematocrit with a two step DC analysis technique is provided. Then a pulse wave is not required, so this method may be utilized in states of low blood pressure or low blood flow.
Owner:HEMA METRICS
Surgical instrument with detection sensors
ActiveUS20170296178A1Diagnostics using lightDiagnostics using pressureSmall form factorSurgical site
Aspects of the present disclosure are presented for a surgical instrument having one or more sensors at or a near an end effector and configured to aide in the detection of tissues and other materials and structures at a surgical site. The detections may then be used to aide in the placement of the end effector and to confirm which objects to operate on, or alternatively, to avoid. Examples of sensors include laser sensors used to employ Doppler shift principles to detect movement of objects at the surgical site, such as blood cells; resistance sensors to detect the presence of metal; monochromatic light sources that allow for different levels of absorption from different types of substances present at the surgical site, and near infrared spectrometers with small form factors.
Owner:CILAG GMBH INT
Method and apparatus for improving the accuracy of noninvasive hematocrit measurements
A device and a method to provide a more reliable and accurate measurement of hematocrit (Hct) by noninvasive means. The changes in the intensities of light of multiple wavelengths transmitted through or reflected light from the tissue location are recorded immediately before and after occluding the flow of venous blood from the tissue location with an occlusion device positioned near the tissue location. As the venous return stops and the incoming arterial blood expands the blood vessels, the light intensities measured within a particular band of near-infrared wavelengths decrease in proportion to the volume of hemoglobin in the tissue location; those intensities measured within a separate band of wavelengths in which water absorbs respond to the difference between the water fractions within the blood and the displaced tissue volume. A mathematical algorithm applied to the time-varying intensities yields a quantitative estimate of the absolute concentration of hemoglobin in the blood. To compensate for the effect of the unknown fraction of water in the extravascular tissue on the Hct measurement, the tissue water fraction is determined before the occlusion cycle begins by measuring the diffuse transmittance or reflectance spectra of the tissue at selected wavelengths.
Owner:COVIDIEN LP
Preservation of fetal nucleic acids in maternal plasma
ActiveUS20100184069A1Maintain structural integrityInhibition releaseMicrobiological testing/measurementRibonucleaseLysis
A method for preserving and processing fetal nucleic acids located within maternal plasma is disclosed, wherein a sample of maternal blood containing fetal nucleic acids is treated to reduce both cell lysis of the maternal blood cells and deoxyribonuclease (DNase) and ribonuclease (RNase) activity within the fetal nucleic acids. The treatment of the sample aids in increasing the amount of fetal nucleic acids that can be identified and tested while maintaining the structure and integrity of the fetal nucleic acids.
Owner:STRECK LLC
Transfection of blood cells with mRNA for immune stimulation and gene therapy
InactiveUS20060188490A1Improve stabilityIncrease transfectionSsRNA viruses negative-senseBiocideAntigenCancer prevention
The present invention relates to a pharmaceutical composition containing blood cells or haemopoietic cells, e.g. red blood cells (erythrocytes), granulocytes, mononuclear cells (PBMCs) and / or blood platelets, in combination with a pharmaceutically acceptable excipient and / or vehicle, wherein the cells are transfected with at least one mRNA comprising at least one region coding for at least one antigen. The invention further discloses a method of preparing the aforesaid pharmaceutical composition and the use of blood cells transfected in this way for the preparation of drugs or pharmaceutical compositions for immune stimulation against the antigens encoded by the mRNA. The subjects according to the invention are used especially for the therapy and / or prophylaxis of carcinoses or infectious diseases and can also be employed in gene therapy.
Owner:CUREVAC AG
Pumping cartridge having an integrated filter and method for filtering a fluid with the cartridge
InactiveUS6905479B1Positive displacement pump componentsOther blood circulation devicesParticulatesEngineering
The present invention involves, in some embodiments, reusable pump drive systems, which are coupled to removable, and preferably disposable, pumping cartridges. The invention provides, in some embodiments, novel pumping cartridges for use in pumping systems. One such cartridge includes an integrated filter element therein for filtering fluids, for example fluids pumped to the body of a patient in a medical procedure. In some embodiments, the integrated filter is utilized as a blood clot removal filter and in other embodiments is used to remove particulates liquids infused to a patient. The filter element includes a filter with pores therein that are preferably sized to permit essentially unrestricted flow of individual human blood cells therethrough and to block or collect blood clots, cell clumps, particulates etc. with sizes substantially larger than the average size of a human blood cell.
Owner:DEKA PROD LLP
Disposable test strips with integrated reagent/blood separation layer
An improved disposable glucose test strip for use in a test meter of the type which receives a disposable test strip and a sample of blood from a patient and performs an electrochemical analysis using a non-conductive integrated reagent / blood separation layer (17) containing a filler, an enzyme effective to oxidize glucose, e.g., glucose oxidase, and a mediator effective to transfer electrons from the enzyme. The integrated layer formulation is printed over a conductive carbon element (16) to form a working electrode. The filler, for example a silica filler, is selected to have a balance of hydrophobicity such that on drying it forms a two-dimensional network on the surface of the conductive element. The response of this test strip is essentially temperature independent over relevant temperature ranges and is substantially insensitive to the hematocrit of the patient.
Owner:SELFCARE +1
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
InactiveUS20040220144A1Extension of timeBiocidePeptide/protein ingredientsBULK ACTIVE INGREDIENTActive ingredient
Methods of treating, preventing and / or managing myclodysplastic syndromes are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient, and / or the transplantation of blood or cells. Specific second active ingredients are capable of affecting or blood cell production. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Owner:CELGENE CORP
System and method for measuring an analyte in a sample
ActiveUS20090184004A1Interference minimizationLess of concentration profileImmobilised enzymesBioreactor/fermenter combinationsAnalyteConcentrations glucose
Methods of determining a corrected analyte concentration in view of some error source are provided herein. The methods can be utilized for the determination of various analytes and / or various sources of error. In one example, the method can be configured to determine a corrected glucose concentration in view of an extreme level of hematocrit found within the sample. In other embodiments, methods are provided for identifying various system errors and / or defects. For example, such errors can include partial-fill or double-fill situations, high track resistance, and / or sample leakage. Systems are also provided for determining a corrected analyte concentration and / or detecting some system error.
Owner:LIFESCAN IP HLDG LLC
Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations
InactiveUS6890421B2Weather/light/corrosion resistanceMicrobiological testing/measurementAnalyteBlood cell
Methods and devices for determining the concentration of an analyte in a physiological sample are provided which correct for errors in the analyte concentration measurement which are due to the hematocrit of the sample.
Owner:LIFESCAN IP HLDG LLC
Human cord blood as a source of neural tissue for repair of the brain and spinal cord
InactiveUS20020028510A1Easy to distinguishImprove neurological dysfunctionNervous disorderCell differentiationDiseaseCord blood stem cell
The present invention relates to the use of umbilical cord blood cells from a donor or patient to provide neural cells which may be used in transplantation. The isolated cells according to the present invention may be used to effect autologous and allogeneic transplantation and repair of neural tissue, in particular, tissue of the brain and spinal cord and to treat neurodegenerative diseases of the brain and spinal cord.
Owner:SANERON CCEL THERAPEUTICS +1
Invertible filter for embolic protection
A medical device including a guiding member and a filter portion is disclosed. The guiding member includes a lumen configured to slidably engage the filter portion. The filter portion forms a tubular geometry that extends distally from the guiding member. The filter portion is configured to evert to form a proximally facing concave geometry for capturing emboli. Further, the filter portion includes filter openings that are sized to allow blood cells to pass therethrough while preventing the passage of emboli.
Owner:COOK MEDICAL TECH LLC
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
Methods of treating, preventing and / or managing myclodysplastic syndromes are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient, and / or the transplantation of blood or cells. Specific second active ingredients are capable of affecting or blood cell production. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Owner:CELGENE CORP
Electrochemical biosensor
ActiveUS20050000808A1Reduced hematocrit level-dependent biasImprove manufacturabilityImmobilised enzymesBioreactor/fermenter combinationsElectron transfer mediatorElectrochemical biosensor
There is provided the reagent layer composition that can substantially reduce the measurement bias arising from hematocrits. The addition of fatty acid (4-20 carbons) and quaternary ammonium salt to a commonly used reagent layer composition composed of an enzyme, an electron transfer mediator, and several water soluble polymers not only reduce the hematocrit level-dependent bias but also provide very stable performance for an extended period of time. Disclosed are also various types of sub microliter sample volume electrochemical biosensors that are suitable to use with the reagent layer composition of present invention.
Owner:I SENS INC
Biosensor having improved hematocrit and oxygen biases
ActiveUS7501053B2Accurate responseDesensitizationImmobilised enzymesBioreactor/fermenter combinationsQuinoneManganese
A biosensor that utilizes a mediator, i.e., an isomer of phenanthroline quinone, 1,10-phenanthroline-5,6-dione, and a metal ion, such as manganese, with an enzyme dependent upon NAD(P)+, such as, for example, glucose dehydrogenase, for improving the hematocrit bias and oxygen bias of biosensors. The electrodes of the biosensors employing this mediator and a metal ion provide an accurate clinical response over a hematocrit range that ranges from about 20% to about 70% and over an oxygen tension range that ranges from about 1 kPa to about 20 kPa.
Owner:ABBOTT DIABETES CARE INC
Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations
InactiveUS20050176153A1Electrolysis componentsVolume/mass flow measurementElectrical batteryBlood cell
Owner:LIFESCAN INC
Microfluidic devices and methods for cell sorting, cell culture and cells based diagnostics and therapeutics
ActiveUS20140248621A1Uniform pressure distributionReduce widthHeating or cooling apparatusMicrobiological testing/measurement3D cell cultureTumor cells
Microfluidic devices and methods that use cells such as cancer cells, stem cells, blood cells for preprocessing, sorting for various biodiagnostics or therapeutical applications are described. Microfluidics electrical sensing such as measurement of field potential or current and phenomena such as immiscible fluidics, inertial fluidics are used as the basis for cell and molecular processing (e.g., characterizing, sorting, isolation, processing, amplification) of different particles, chemical compositions or biospecies (e.g., different cells, cells containing different substances, different particles, different biochemical compositions, proteins, enzymes etc.). Specifically this invention discloses a few sorting schemes for stem cells, whole blood and circulating tumor cells and also extracting serum from whole blood. Further medical diagnostics technology utilizing high throughput single cell PCR is described using immiscible fluidics couple with single or multi cells trapping technology.
Owner:BIOPICO SYST
Method of measuring blood component, sensor used in the method, and measuring device
ActiveUS20070131565A1Easy to measureImprove accuracyImmobilised enzymesBioreactor/fermenter combinationsOxidoreductasePhysics
The present invention provides a method of measuring a component in blood, by which an amount of the component can be corrected accurately by measuring a hematocrit (Hct) value of the blood with high accuracy and high reliability and also provides a sensor used in the method. The sensor for measuring a component in blood has a first analysis portion and a second analysis portion. The first analysis portion has a first electrode system (11,12) and a reagent layer (14), and the reagent layer (14) has an oxidoreductase that acts on the component and a mediator. In the first analysis portion, the component in the blood is measured by causing a redox reaction of the component with the oxidoreductase in the presence of the mediator and detecting a redox current caused when a voltage is applied by the first electrode (11,12). The second analysis portion has a working electrode and a counter electrode, and a mediator is provided on the counter electrode but not on the working electrode. In the second analysis portion, a Hct value of the blood is measured by supplying the blood to the electrode system, applying a voltage to cause a current to flow, and detecting a value of the current. Using this Hct value, the amount of the component is corrected.
Owner:PHC HLDG CORP
Blood monitoring system
InactiveUS20060229531A1Improve accuracyMechanical/radiation/invasive therapiesMedical devicesBlood chemistryBlood parameters
The present invention is directed towards apparatuses and methods for the automated measurement of blood analytes and blood parameters for bedside monitoring of patient blood chemistry. Particularly, the current invention discloses a programmable system that can automatically draw blood samples at a suitable programmable time frequency (or at predetermined timing), can automatically analyze the drawn blood samples and immediately measure and display blood parameters such as glucose levels, hematocrit levels, hemoglobin blood oxygen saturation, blood gases, lactate or any other blood parameter.
Owner:GLUCON
Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
The present invention relates to hematopoietic stem and progenitor cells of neonatal or fetal blood that are cryopreserved, and the therapeutic uses of such stem and progenitor cells upon thawing. In particular, the present invention relates to the therapeutic use of fetal or neonatal stem cells for hematopoietic (or immune) reconstitution. Hematopoietic reconstitution with the cells of the invention can be valuable in the treatment or prevention of various diseases and disorders such as anemias, malignancies, autoimmune disorders, and various immune dysfunctions and deficiencies. In another embodiment, fetal or neonatal hematopoietic stem and progenitor cells which contain a heterologous gene sequence can be used for hematopoietic reconstitution in gene therapy. In a preferred embodiment of the invention, neonatal or fetal blood cells that have been cryopreserved and thawed can be used for autologous (self) reconstitution.
Owner:PHARMASTEM THERAPEUTICS
Biosensor
InactiveUS6706232B2Avoid destructionNot easy to dissolveImmobilised enzymesBioreactor/fermenter combinationsWhole blood unitsEngineering
There is provided a cholesterol sensor with high-accuracy and excellent response, whose object to be measured is whole blood, where plasma with hemocytes therein filtered can rapidly reach an electrode system. In a biosensor where plasma with hemocytes therein filtered with a filter is sucked into a sample solution supply pathway due to capillarity, there are formed: a first pressing part for holding a primary side portion of the filter from the bottom; a second pressing part for holding a secondary side portion of the filter from the top and the bottom; a third pressing part for holding the central portion of the filter from the top; and a void for surrounding the filter between the second pressing part and third pressing part.
Owner:PANASONIC CORP
Electrochemical biosensor
ActiveUS7288174B2Reduced hematocrit level-dependent biasImprove manufacturabilityImmobilised enzymesBioreactor/fermenter combinationsElectron transfer mediatorElectrochemical biosensor
There is provided the reagent layer composition that can substantially reduce the measurement bias arising from hematocrits. The addition of fatty acid (4-20 carbons) and quaternary ammonium salt to a commonly used reagent layer composition composed of an enzyme, an electron transfer mediator, and several water soluble polymers not only reduce the hematocrit level-dependent bias but also provide very stable performance for an extended period of time. Disclosed are also various types of sub microliter sample volume electrochemical biosensors that are suitable to use with the reagent layer composition of present invention.
Owner:I SENS INC
Differentiation-suppressive polypeptide
InactiveUS6337387B1Improve physiological activityEasily mutatePeptide/protein ingredientsDepsipeptidesGeneMedical treatment
A polypeptide which contains the amino acid sequence described in SEQ ID NO: 1 in the Sequence Listing encoded by a gene originating in human being. Because of serving as a chemical efficacious in the supression of the proliferation and defferentiation of undifferentiated blood cells. this polypeptide is expected to be usable in medicines and medical supplies.
Owner:ASAHI KASEI KK
Preservation of cell-free nucleic acids
ActiveUS20100209930A1Prevent leakageInhibit synthesisMicrobiological testing/measurementChemical inhibitorsLysisNuclease
A method for preserving and processing cell-free nucleic acids located within a blood sample is disclosed, wherein a blood sample containing cell-free nucleic acids is treated to reduce both blood cell lysis and nuclease activity within the blood sample. The treatment of the sample aids in increasing the amount of cell-free nucleic acids that can be identified and tested while maintaining the structure and integrity of the nucleic acids.
Owner:STRECK LLC
Analyte detection devices and methods with hematocrit/volume correction and feedback control
InactiveUS20060281187A1Accurately efficiently economically determiningOvercomes shortcomingAnalysis using chemical indicatorsMaterial analysis by observing effect on chemical indicatorAnalyteDetector array
Disclosed are devices, arrangements and methods for quantifying the concentration of an analyte present in bodily fluid, including: an assay pad having at least one chemical reagent capable of producing a detectable signal in the form of a reaction spot upon reaction with the analyte; a light source; a detector array; a processor; and a memory in communication with the processor, the memory comprising: (a) at least one value indicative of one or more of: (i) the level of hematocrit contained in the sample; (ii) the volume of the sample applied to the assay pad; or (iii) imperfections present in the reaction spot; and (b) at least one algorithm for calculating the concentration of the analyte contained in the sample.
Owner:INTUITY MEDICAL INC
Blood testing tool
A blood testing tool is provided, which separates blood cells and can collect blood plasma or blood serum with a high yield. The blood testing tool includes an asymmetric porous membrane with a pore size distribution in which an average pore size varies to be reduced continuously or discontinuously in a thickness direction. The porous membrane includes a blood supply portion, a development portion, and a blood-cell blocking portion formed between the blood supply portion and the development portion and pores in the blood cell blocking portion include only pores through which blood cells cannot pass. When blood is supplied to one side with larger pores of the blood supply portion, the blood moves in a direction parallel to a surface of the porous membrane by a capillary phenomenon, but only blood plasma or blood serum moves into the development portion to develop.
Owner:ARKRAY INC
Apparatus and method for separation of particles suspended in a liquid from the liquid in which they are suspended
InactiveUS20100078384A1Improve concentrationAvoid turbulenceSemi-permeable membranesLiquid separation by electricityUltrasonic sensorCompressibility
A method for separating, or removing, particulate material, e.g., blood cells, from a sample of fluid, e.g., whole blood of a patient, in which the particulate material is suspended. In the case of separating blood cells from blood plasma or blood serum, the resulting samples of blood plasma or blood serum can be used for in vitro diagnostic applications. In normal practice, a whole blood sample of a patient are provided and then introduced into an apparatus that contains a flow channel. An acoustic field, which contains acoustic standing waves from external ultrasonic transducers, is located within the flow channel. Laminar flow is maintained in the flow channel. Blood cells and platelets are separated from blood plasma or blood serum at the end of the flow channel and collected. The method described herein allows fluid components to differentially migrate to areas of preferred acoustic interaction. The parameters that affect separation of particles are size, density, compressibility of the particles, and the fluid surrounding the particles.
Owner:ABBOTT LAB INC
Transfection of blood cells with mRNA for immune stimulation and gene therapy
InactiveUS20120009221A1Improve stabilityIncrease transfectionSsRNA viruses negative-senseViral antigen ingredientsAntigenPharmaceutical medicine
The present invention relates to a pharmaceutical composition containing blood cells or haemopoietic cells, e.g. red blood cells (erythrocytes), granulocytes, mononuclear cells (PBMCs) and / or blood platelets, in combination with a pharmaceutically acceptable excipient and / or vehicle, wherein the cells are transfected with at least one mRNA comprising at least one region coding for at least one antigen. The invention further discloses a method of preparing the aforesaid pharmaceutical composition and the use of blood cells transfected in this way for the preparation of drugs or pharmaceutical compositions for immune stimulation against the antigens encoded by the mRNA. The subjects according to the invention are used especially for the therapy and / or prophylaxis of carcinoses or infectious diseases and can also be employed in gene therapy.
Owner:CUREVAC AG
System for cell enrichment
Owner:ARTEMIS HEALTH INC +2
Analyte determination method and analyte meter
The presence of oxygen or red blood cells in a sample applied to an electrochemical test strip that makes use of a reduced mediator is corrected for by an additive correction factor that is determined as a function of the temperature of the sample and a measurement that reflects the oxygen carrying capacity of the sample. The measured oxygen carrying capacity can also be used to determine hematocrit and to distinguish between blood samples and control solutions applied to a test strip.
Owner:AGAMATRIX INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com